JP2020531524A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531524A5 JP2020531524A5 JP2020511314A JP2020511314A JP2020531524A5 JP 2020531524 A5 JP2020531524 A5 JP 2020531524A5 JP 2020511314 A JP2020511314 A JP 2020511314A JP 2020511314 A JP2020511314 A JP 2020511314A JP 2020531524 A5 JP2020531524 A5 JP 2020531524A5
- Authority
- JP
- Japan
- Prior art keywords
- her2
- mva
- cancer
- cells
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17187824 | 2017-08-24 | ||
| EP17187824.2 | 2017-08-24 | ||
| PCT/EP2018/072789 WO2019038388A1 (en) | 2017-08-24 | 2018-08-23 | POLYTHERAPY FOR THE TREATMENT OF CANCER BY INTRAVENOUS ADMINISTRATION OF RECOMBINANT MVA AND ANTIBODY |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020531524A JP2020531524A (ja) | 2020-11-05 |
| JP2020531524A5 true JP2020531524A5 (cg-RX-API-DMAC7.html) | 2022-09-07 |
| JP7202362B2 JP7202362B2 (ja) | 2023-01-11 |
Family
ID=59702586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511314A Active JP7202362B2 (ja) | 2017-08-24 | 2018-08-23 | 組み換えmva及び抗体の静脈内投与を用いた、がん治療のための併用療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11273211B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3691675A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7202362B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102754876B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111050790B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018320417B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020003669A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3073310A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL272546B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020001856A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202001115TA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019038388A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| EP4061405A1 (en) | 2019-11-18 | 2022-09-28 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
| BR112022009798A2 (pt) * | 2019-11-20 | 2022-10-18 | Bavarian Nordic As | Vírus mva recombinante para administração intratumoral e/ou intravenosa para tratamento de câncer |
| JP7670705B2 (ja) * | 2019-11-20 | 2025-04-30 | バヴァリアン・ノルディック・アクティーゼルスカブ | 4-1bblアジュバント添加した組み換え改変ワクシニアウイルスアンカラ(mva)の医学的使用 |
| AU2021252164B2 (en) | 2020-04-09 | 2026-07-02 | Finncure Oy | Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses |
| US12194157B2 (en) | 2020-04-09 | 2025-01-14 | Finncure Oy | Carrier for targeted delivery to a host |
| AU2021294322A1 (en) * | 2020-06-26 | 2023-02-02 | National Breast Cancer Coalition | Breast cancer vaccine |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| WO2022009049A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| US20240182568A1 (en) * | 2021-03-10 | 2024-06-06 | University Of Iowa Research Foundation | Methods of enhancing antibody therapies |
| US20240226233A1 (en) * | 2021-05-03 | 2024-07-11 | L&C Bio Co., Ltd. | Composition comprising zag-derived peptide for improving scars and keloids |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766598A (en) | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
| EP0954593A1 (en) | 1996-07-25 | 1999-11-10 | Therion Biologics Corporation | Recombinant pox virus for immunization against tumor-associated antigens |
| EP1865065A1 (en) * | 1998-12-09 | 2007-12-12 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
| HU230198B1 (hu) | 2000-11-23 | 2015-10-28 | Bavarian Nordic A/S | Módosított Vacciniavírus Ankara-variáns |
| DE60235041D1 (de) | 2001-11-30 | 2010-02-25 | Us Gov Health & Human Serv | Und ihre verwendung |
| EP1456230A2 (en) | 2001-12-04 | 2004-09-15 | Bavarian Nordic A/S | Flavivirus ns1 subunit vaccine |
| EP1649020B1 (en) | 2003-07-21 | 2017-01-11 | MSD Italia S.r.l. | Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof |
| CA2741724C (en) | 2008-11-27 | 2016-10-04 | Bavarian Nordic A/S | Promoters for recombinant viral expression |
| US8394385B2 (en) | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| ES2660597T3 (es) * | 2009-04-17 | 2018-03-23 | Globeimmune, Inc. | Composiciones inmunoterápicas de combinación contra el cáncer y métodos |
| US10111946B2 (en) | 2012-06-22 | 2018-10-30 | Bavarian Nordic A/S | Poxviral vectors for low antibody response after a first priming immunization |
| EP2892549A1 (en) * | 2012-09-04 | 2015-07-15 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
| WO2014043535A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions for the treatment of cancer |
| WO2014043518A1 (en) * | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use |
| EP2908851A1 (en) | 2012-10-19 | 2015-08-26 | Bavarian Nordic Inc. | Methods and compositions for the treatment of cancer |
| MX380483B (es) | 2012-10-28 | 2025-03-12 | Bavarian Nordic As | Promotor pr13.5 para respuestas de anticuerpos y linfocitos t fuertes. |
| US9725494B2 (en) * | 2013-05-17 | 2017-08-08 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Soluble CD27 (sCD27) and the use thereof |
| JP6535337B2 (ja) | 2013-11-05 | 2019-06-26 | バヴァリアン・ノルディック・アクティーゼルスカブ | 腫瘍抗原を発現するポックスウイルスならびに免疫チェックポイント阻害剤のアンタゴニスト及び/またはアゴニストにより癌を治療するための組み合わせ療法 |
| ES2895977T3 (es) * | 2013-11-28 | 2022-02-23 | Bavarian Nordic As | Composiciones y métodos de inducción de una respuesta inmunitaria mejorada usando vectores de poxvirus |
| DK3142690T3 (da) * | 2014-05-13 | 2022-05-09 | Bavarian Nordic As | Kombinationsterapi til behandling af cancer med et rekombinant poxvirus, der eksprimerer et tumorantigen, og en immun-checkpointmolekyleantagonist eller -agonist |
| US20170196953A1 (en) | 2014-07-07 | 2017-07-13 | Duke University | VACCINES AGAINST AN ONCOGENIC ISOFORM OF HER2 (ErbB2) AND METHODS OF USING THE SAME |
| CA2960087C (en) * | 2014-09-26 | 2024-02-27 | Bavarian Nordic A/S | Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin |
| DK3329016T3 (da) | 2015-07-31 | 2022-01-10 | Bavarian Nordic As | Promotorer til forbedring af ekspression i poxvirus |
| JP7625518B2 (ja) * | 2018-11-20 | 2025-02-03 | バヴァリアン・ノルディック・アクティーゼルスカブ | 4-1bbl(cd137l)及び/またはcd40lをコードする組み換えmvaの腫瘍内及び/または静脈内投与によって、がんを治療する療法 |
| JP7670705B2 (ja) * | 2019-11-20 | 2025-04-30 | バヴァリアン・ノルディック・アクティーゼルスカブ | 4-1bblアジュバント添加した組み換え改変ワクシニアウイルスアンカラ(mva)の医学的使用 |
| WO2023118508A1 (en) * | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
-
2018
- 2018-08-23 IL IL272546A patent/IL272546B2/en unknown
- 2018-08-23 SG SG11202001115TA patent/SG11202001115TA/en unknown
- 2018-08-23 CN CN201880054776.8A patent/CN111050790B/zh active Active
- 2018-08-23 KR KR1020207005076A patent/KR102754876B1/ko active Active
- 2018-08-23 WO PCT/EP2018/072789 patent/WO2019038388A1/en not_active Ceased
- 2018-08-23 JP JP2020511314A patent/JP7202362B2/ja active Active
- 2018-08-23 AU AU2018320417A patent/AU2018320417B2/en active Active
- 2018-08-23 CA CA3073310A patent/CA3073310A1/en active Pending
- 2018-08-23 EP EP18756447.1A patent/EP3691675A1/en active Pending
- 2018-08-23 MX MX2020001856A patent/MX2020001856A/es unknown
- 2018-08-23 US US16/641,236 patent/US11273211B2/en active Active
- 2018-08-23 BR BR112020003669-2A patent/BR112020003669A2/pt active Search and Examination
-
2022
- 2022-03-14 US US17/693,716 patent/US11723964B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11723964B2 (en) | Combination therapy for treating cancer with an antibody and intravenous administration of a recombinant MVA | |
| AU2019385665B2 (en) | Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-ibbl (cd137l) and/or cd40l | |
| JP7555334B2 (ja) | 組み換えmva、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法 | |
| JP7644111B2 (ja) | がんを治療するための腫瘍内及び/または静脈内投与用組み換えmvaウイルス | |
| EP4452305A1 (en) | Recombinant mva viruses for intraperitoneal administration for treating cancer | |
| US20250002606A1 (en) | Combination Therapy for Treating Cancer with an Antibody and Intravenous Administration of a Recombinant MVA | |
| RU2795103C2 (ru) | Комбинированная терапия для лечения рака путем внутривенного введения рекомбинантного mva и антитела | |
| CA3240596A1 (en) | Therapy for modulating immune response with recombinant mva encoding il-12 |